Accession Number:

ADA416075

Title:

Preclinical Pharmacodynamic and Pharmacokinetic Studies of Investigational New Drugs

Descriptive Note:

Annual rept. 8 Sep 2001-7 Sep 2002

Corporate Author:

SOUTHERN RESEARCH INST BIRMINGHAM AL

Personal Author(s):

Report Date:

2002-10-01

Pagination or Media Count:

80.0

Abstract:

A study was conducted to investigate the pharmacodynamic effects, as assessed by signs of clinical and pathological toxicity, of artelinate AL given as an L-lysine salt and artesunate AS in male and female Sprague-Dawley rats given single or multiple intravenous iv doses via a tail vein intramuscular im administered arteether AE served as the positive control for the formation of neurotoxicological lesions. For rats given single iv doses, mortality was observed at AL doses of greater than or equal to 160 mgkg and at an AS dose of 400 mgkg. Following 7 consecutive days of iv dose administration, no mortality was observed for male and female rats given less than or equal to 37.5 mgkgday of AL total dose less than or equal to 262.5 mgkg or less than or equal to 75 mgkgday of AS total dose less than or equal to 525 mgkg. Due to the difficulty encountered during the iv administration of AL, no conclusions could be drawn relative to the lethality produced by higher multiple iv doses of AL. Single or multiple iv dose administration of AL produced a possible dose-dependent venotoxicity that was characterized by black andor dark discoloration of the tail, which in some instances was accompanied by necrosis. Clinical pathological changes observed for rats given iv doses of 80 mgkgday of AL for less than or equal to 4 days or 150 mgkgday of AS for 7 consecutive days were consistent with an effect on hematopoiesis. No evidence was obtained for the presence of histopathological lesions in the hindbrains of rats given less than or equal to 37.5 mgkgday of AL for 7 consecutive days or less than or equal to 150 mgkgday of AS for 7 consecutive days.

Subject Categories:

  • Medicine and Medical Research
  • Pharmacology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE